scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1025001520 |
P356 | DOI | 10.1007/BF00157408 |
P698 | PubMed publication ID | 8243605 |
P2093 | author name string | F Barchiesi | |
G Scalise | |||
V Morbiducci | |||
F Ancarani | |||
P2860 | cites work | Increase inCandida kruseiInfection among Patients with Bone Marrow Transplantation and Neutropenia Treated Prophylactically with Fluconazole | Q43543160 |
Mucosal candidiasis caused by non-albicans species of Candida in HIV-positive patients | Q44881498 | ||
Fluconazole and Candida krusei fungemia. | Q54286404 | ||
Candida krusei sepsis in HIV infection | Q68016905 | ||
P433 | issue | 4 | |
P921 | main subject | candidiasis | Q273510 |
Candida albicans | Q310443 | ||
P304 | page(s) | 455-456 | |
P577 | publication date | 1993-07-01 | |
P1433 | published in | European Journal of Epidemiology | Q5412723 |
P1476 | title | Emergence of oropharyngeal candidiasis caused by non-albicans species of Candida in HIV-infected patients | |
P478 | volume | 9 |
Q41754780 | Antifungal therapy in the oral cavity |
Q34721925 | Candida glabrata Esophagitis: Are We Seeing the Emergence of a New Azole-Resistant Pathogen? |
Q28264860 | Echinocandins in the management of invasive fungal infections, Part 2 |
Q47646968 | Fluconazole Resistance among Oral Candida Isolates from People Living with HIV/AIDS in a Nigerian Tertiary Hospital |
Q58760701 | Human defects in STAT3 promote oral mucosal fungal and bacterial dysbiosis |
Q77931985 | In vitro activities of antimicrobial agents against Candida species |
Q33685839 | Nosocomial fungal infections: candidemia |
Q34633796 | Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection |
Q40827662 | Options for the management of mucosal candidiasis in patients with AIDS and HIV infection |
Q45399634 | Oral Candida colonization of human immunodeficiency virus infected subjects in Turkey and its relation with viral load and CD4+ T-lymphocyte count |
Q34041589 | Oral Candida isolates colonizing or infecting human immunodeficiency virus-infected and healthy persons in Mexico |
Q45050994 | Oropharyngeal candidiasis in HIV-infected patients under treatment with protease inhibitors |
Q46656032 | Point prevalence, microbiology and antifungal susceptibility patterns of oral Candida isolates colonizing or infecting Mexican HIV/AIDS patients and healthy persons. |
Q40188971 | Posaconazole for the management of mucosal candidiasis |
Q73590280 | Prevalence and antifungal susceptibility of vaginal yeasts in outpatients attending a gynecological center in Ancona, Italy |
Q35110522 | Resistance of Candida species to fluconazole |
Q36642964 | Role of posaconazole in the management of oropharyngeal and esophageal candidiasis |
Q36528018 | Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome |
Q33788619 | The use of fluconazole and itraconazole in the treatment of Candida albicans infections: a review |
Search more.